NHS Improving Quality and NHS England are working nationally with the Academic Health Science Networks to provide support and opportunities for the Collaboratives to learn from each other, ensuring the most effective and successful solutions are rapidly spread and adopted across England.
For the next five years, each Collaborative will support individuals, teams and organisations to build skills and knowledge about patient safety and quality improvement to create space and time to work on the challenges, and provide opportunities to learn from each other.
The programme is borne out of Professor Don Berwick's report last year into the safety of patients in England and builds on learning from the Francis and Winterbourne View recommendations. The report, A Promise to Learn - a commitment to act, made a series of recommendations to improve patient safety; and called for the NHS ''to become, more than ever before, a system devoted to continual learning and improvement of patient care, top to bottom and end to end.'
Aligned with and supporting the 'Sign up to Safety' campaign, the programme aims to make the NHS the safest healthcare system in the world by creating the culture to support a system devoted to continuous learning and improvement.
This resource summarises the Patient Safety Collaboratives current priority plans. Some of these plans are in consultation with partner organisations and may be subject to change. - See more at: http://www.nhsiq.nhs.uk/resource-search/publications/safety-collaborative-plans.aspx#sthash.O5lUFIQf.dpuf
Have you ever struggled to unite a team on an improvement project? Or have you ever been in a situation where lack of communication has hindered your improvement efforts?
Presentation by Alan Dubovsky, Chief Patient Experience Officer, Cedars Sinai Medical Center, about their Patient Experience Program. Begins with a review of patient satisfaction scores, clinical performance initiatives, medical outcomes, ongoing research, academic programs, and national awards. Next is a timeline of activites, from building the PX Infrastructure, PX Improvement Projects, Launching PX Skill Building Programs and introducing PX Innovation. Includes details about the Primary functions of the office of Patient Experience:
The measurement, reporting, and analysis of all Patient Feedback and the coordination and implementation of all Patient Experience improvement efforts across the health system. The patient voice is captured through Solicited Feedback, Patient & Family Advisor Programs and Verbatim Feedback. Presentation finishes with a discussion about the Future Of Patient Feedback. Some of those areas: Using patient segmentation to group patients into distinct segments, Asking patients unique questions to understand their primary concerns, Asking planned admissions who helped set their expectations?
Asking new patients what was their prior perception compared to reality?
mHealth Israel_Innovation reaching the Voice of the Patient_SiemensLevi Shapiro
Innovation reaching the Voice of the Patient, lecture by Christina Triantafyllou, Ph.D, Head of Improving Patient Experience at Siemens Healthineers. Key Sections:
Pushing the boundaries with Innovation
Translate innovation into patient experience
The voice of patients is becoming increasingly important
Improving patient experience
We enable healthcare providers to increase value by Improving patient experience
The biggest levers to optimize the patient diagnostic experience are the three core dimensions: staff, process, and equipment
Steps to deliver outcomes that matter to patients
We enable healthcare providers to increase value by Improving patient experience
Identify the right priorities: What are the factors influencing the patient experience across the continuum of care?
Patient experience during COVID-19
Patients feel uncomfortable to seek care
Five lessons learned so far
Patient experience in times of COVID-19
Patient Journey
HXR 2016: Human Focused Innovation in a Clinical Setting -Lesley Solomon, Bri...HxRefactored
This section of the agenda will feature leaders in innovation, patient experience, and design within a clinical setting. Each panelist will present the current state of experiential innovation at their organization, what successes they have seen, what situations they have learned from, and what their challenges and obstacles are, and where they would like to see things head in the future. Then Amy Cueva will guide the group in a discussion around strategy, measurement, culture change, and other important topics relevant to delivering phenomenal experiences.
Virtual knowledge network NIMHANS Echo : Innovative tele- mentoring model for skilled capacity building in addiction & mental health by Prabhat Chand , NIMHANS, India
When the Human Genome Project was declared complete back in 2003, there were high expectations set for genomic medicine. However, it has taken over a decade to begin moving from vision to reality. Today, the number of success stories remains relatively small, but they do stretch across the healthcare ecosystem, incorporating the prediction of drug responses, the diagnosis of diseases and the identification of targeted therapies. Stakeholders ranging from patients, healthcare providers and payers, researchers, diagnostic companies, policy-makers, life sciences businesses and governments now believe genomic medicine to be a potential game-changer
NHS Improving Quality and NHS England are working nationally with the Academic Health Science Networks to provide support and opportunities for the Collaboratives to learn from each other, ensuring the most effective and successful solutions are rapidly spread and adopted across England.
For the next five years, each Collaborative will support individuals, teams and organisations to build skills and knowledge about patient safety and quality improvement to create space and time to work on the challenges, and provide opportunities to learn from each other.
The programme is borne out of Professor Don Berwick's report last year into the safety of patients in England and builds on learning from the Francis and Winterbourne View recommendations. The report, A Promise to Learn - a commitment to act, made a series of recommendations to improve patient safety; and called for the NHS ''to become, more than ever before, a system devoted to continual learning and improvement of patient care, top to bottom and end to end.'
Aligned with and supporting the 'Sign up to Safety' campaign, the programme aims to make the NHS the safest healthcare system in the world by creating the culture to support a system devoted to continuous learning and improvement.
This resource summarises the Patient Safety Collaboratives current priority plans. Some of these plans are in consultation with partner organisations and may be subject to change. - See more at: http://www.nhsiq.nhs.uk/resource-search/publications/safety-collaborative-plans.aspx#sthash.O5lUFIQf.dpuf
Have you ever struggled to unite a team on an improvement project? Or have you ever been in a situation where lack of communication has hindered your improvement efforts?
Presentation by Alan Dubovsky, Chief Patient Experience Officer, Cedars Sinai Medical Center, about their Patient Experience Program. Begins with a review of patient satisfaction scores, clinical performance initiatives, medical outcomes, ongoing research, academic programs, and national awards. Next is a timeline of activites, from building the PX Infrastructure, PX Improvement Projects, Launching PX Skill Building Programs and introducing PX Innovation. Includes details about the Primary functions of the office of Patient Experience:
The measurement, reporting, and analysis of all Patient Feedback and the coordination and implementation of all Patient Experience improvement efforts across the health system. The patient voice is captured through Solicited Feedback, Patient & Family Advisor Programs and Verbatim Feedback. Presentation finishes with a discussion about the Future Of Patient Feedback. Some of those areas: Using patient segmentation to group patients into distinct segments, Asking patients unique questions to understand their primary concerns, Asking planned admissions who helped set their expectations?
Asking new patients what was their prior perception compared to reality?
mHealth Israel_Innovation reaching the Voice of the Patient_SiemensLevi Shapiro
Innovation reaching the Voice of the Patient, lecture by Christina Triantafyllou, Ph.D, Head of Improving Patient Experience at Siemens Healthineers. Key Sections:
Pushing the boundaries with Innovation
Translate innovation into patient experience
The voice of patients is becoming increasingly important
Improving patient experience
We enable healthcare providers to increase value by Improving patient experience
The biggest levers to optimize the patient diagnostic experience are the three core dimensions: staff, process, and equipment
Steps to deliver outcomes that matter to patients
We enable healthcare providers to increase value by Improving patient experience
Identify the right priorities: What are the factors influencing the patient experience across the continuum of care?
Patient experience during COVID-19
Patients feel uncomfortable to seek care
Five lessons learned so far
Patient experience in times of COVID-19
Patient Journey
HXR 2016: Human Focused Innovation in a Clinical Setting -Lesley Solomon, Bri...HxRefactored
This section of the agenda will feature leaders in innovation, patient experience, and design within a clinical setting. Each panelist will present the current state of experiential innovation at their organization, what successes they have seen, what situations they have learned from, and what their challenges and obstacles are, and where they would like to see things head in the future. Then Amy Cueva will guide the group in a discussion around strategy, measurement, culture change, and other important topics relevant to delivering phenomenal experiences.
Virtual knowledge network NIMHANS Echo : Innovative tele- mentoring model for skilled capacity building in addiction & mental health by Prabhat Chand , NIMHANS, India
When the Human Genome Project was declared complete back in 2003, there were high expectations set for genomic medicine. However, it has taken over a decade to begin moving from vision to reality. Today, the number of success stories remains relatively small, but they do stretch across the healthcare ecosystem, incorporating the prediction of drug responses, the diagnosis of diseases and the identification of targeted therapies. Stakeholders ranging from patients, healthcare providers and payers, researchers, diagnostic companies, policy-makers, life sciences businesses and governments now believe genomic medicine to be a potential game-changer
Quality Improvement Strategies: quality improvement tools, factors that help to create and sustain Healthcare Informatics as a new field. quality improvement cycle: PDCA (Plan, Do, Check, Act) Cycle.
Protocols and Evidence based Healthcare: information technology tools to support best practices in health care, information technology tools that inform and empower patients.
"Health Information Exchange in Oregon – Where We Are & Where We Are Going"
Moderator: Eric McLaughlin, Project Manager, Cognosante
Abigail Sears, Chief Executive Officer, OCHIN
Sharon Wentz, RN, Business Development Coordinator, CareAccord
Laurie Miller, RHIT, CCS-P, HISP Administrator, Gorge Health Connect
Paula Weldon, Project Manager, Jefferson Health Information Exchange
The role of the FAIR Guiding Principles in a Learning Health SystemMichel Dumontier
The learning health system (LHS) is a concept for a socio-technological system that continuously improves the delivery of health care by coupling biomedical research with practice- and evidence- based medicine. Key aspects of the LHS are collecting, integrating, and analyzing data from different sources. While the increased digitalisation of healthcare is creating new data sources, these remain hard to find and use, let alone make use of as part of intelligent systems for the benefit of patients, healthcare providers, and researchers. This talk will examine recent developments towards making key parts of the LHS, such as clinical practice guidelines, Findable, Accessible, Interoperable, and Reusable (FAIR).
In this full-day tutorial, you will learn basic overview of electronic medical records systems, health data management and how you can use the OpenMRS system for data and information management. We will cover basics of installation, user management, location management, patient dashboards and some interesting features that are provided by different modules. You can see how OpenMRS can be customized with different modules that are suitable for different contexts. This tutorial is helpful for new users and developers who would like to know the features of OpenMRS. Individuals who would like to evaluate and try to see if OpenMRS fits their healthcare needs will also benefit from this tutorial.
Patient relationship management on the cloudComidor
Healthcare organizations have realized that having long-term relationships with their customers can help improve their satisfaction and general health. As a result they want to build strong relationships with their patients.The best way to achieve that is the use of Patient Relationship Management (PRM).
Jim Warren
National Institute for Health Innovation (NIHI)
The University of Auckland
The presentation was accompanied by this video:
http://www.youtube.com/watch?v=jbvmGqmIxXY
What you need to know about Meaningful Use 2 & interoperabilityCompliancy Group
Does this describe you?
·You are constantly challenged to stay abreast of the latest information on EHR integration and HIE interoperability, Meaningful Use stages, the Direct Project, clinician and patient portals, just to name a few.
·You walk a fine line between adopting health information technology for the good it can bring patient outcomes…….and for the good incentive dollars it can mean to your organization.
·You play a key role in ensuring your organization can attest for meaningful use.
Join Andy Nieto, Health IT Strategist at DataMotion where he’ll explain the key role that interoperability plays in Meaningful Use Stage 2 attestation including:
- What does interoperability really mean
- Why you can’t ignore interoperability
- How to achieve interoperability and make it meaningful
- What you need in order to attest
Patient-Centered Care Requires Patient-Centered Insight: What We Can Do To C...Health Catalyst
Health systems and providers are inundated with measurement systems and reporting. Why would we want to add to the measurement mayhem? The real question is, “Are we measuring what matters?”
Carolyn Simpkins MD, PhD, chief medical informatics officer, will discuss how putting the patient at the center of the measurement matrix can bring coherence and completeness to the picture of care delivery performance across the patient journey, and therefore the performance of the healthcare ecosystem.
She will describe the building blocks for patient-centered measurement and how other metrics, patient-reported outcomes, and patient satisfaction fit into this approach. Carolyn will also review the challenges that have kept health systems from completing a patient-centered outcomes approach and why we are poised to break through. Finally, she will share case studies of organizations who have begun to pioneer the use of patient centered metrics to improve care and outcomes.
People with Chronic Disease needs complete care. The current patient experience will be enhanced with the available technology and by figuring out the ageing population and rising incidence of Chronic Diseases.
Similar to Health Information - A Primary Care Perspective (20)
Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...Oleg Kshivets
RESULTS: Overall life span (LS) was 2252.1±1742.5 days and cumulative 5-year survival (5YS) reached 73.2%, 10 years – 64.8%, 20 years – 42.5%. 513 LCP lived more than 5 years (LS=3124.6±1525.6 days), 148 LCP – more than 10 years (LS=5054.4±1504.1 days).199 LCP died because of LC (LS=562.7±374.5 days). 5YS of LCP after bi/lobectomies was significantly superior in comparison with LCP after pneumonectomies (78.1% vs.63.7%, P=0.00001 by log-rank test). AT significantly improved 5YS (66.3% vs. 34.8%) (P=0.00000 by log-rank test) only for LCP with N1-2. Cox modeling displayed that 5YS of LCP significantly depended on: phase transition (PT) early-invasive LC in terms of synergetics, PT N0—N12, cell ratio factors (ratio between cancer cells- CC and blood cells subpopulations), G1-3, histology, glucose, AT, blood cell circuit, prothrombin index, heparin tolerance, recalcification time (P=0.000-0.038). Neural networks, genetic algorithm selection and bootstrap simulation revealed relationships between 5YS and PT early-invasive LC (rank=1), PT N0—N12 (rank=2), thrombocytes/CC (3), erythrocytes/CC (4), eosinophils/CC (5), healthy cells/CC (6), lymphocytes/CC (7), segmented neutrophils/CC (8), stick neutrophils/CC (9), monocytes/CC (10); leucocytes/CC (11). Correct prediction of 5YS was 100% by neural networks computing (area under ROC curve=1.0; error=0.0).
CONCLUSIONS: 5YS of LCP after radical procedures significantly depended on: 1) PT early-invasive cancer; 2) PT N0--N12; 3) cell ratio factors; 4) blood cell circuit; 5) biochemical factors; 6) hemostasis system; 7) AT; 8) LC characteristics; 9) LC cell dynamics; 10) surgery type: lobectomy/pneumonectomy; 11) anthropometric data. Optimal diagnosis and treatment strategies for LC are: 1) screening and early detection of LC; 2) availability of experienced thoracic surgeons because of complexity of radical procedures; 3) aggressive en block surgery and adequate lymph node dissection for completeness; 4) precise prediction; 5) adjuvant chemoimmunoradiotherapy for LCP with unfavorable prognosis.
Explore natural remedies for syphilis treatment in Singapore. Discover alternative therapies, herbal remedies, and lifestyle changes that may complement conventional treatments. Learn about holistic approaches to managing syphilis symptoms and supporting overall health.
New Directions in Targeted Therapeutic Approaches for Older Adults With Mantl...i3 Health
i3 Health is pleased to make the speaker slides from this activity available for use as a non-accredited self-study or teaching resource.
This slide deck presented by Dr. Kami Maddocks, Professor-Clinical in the Division of Hematology and
Associate Division Director for Ambulatory Operations
The Ohio State University Comprehensive Cancer Center, will provide insight into new directions in targeted therapeutic approaches for older adults with mantle cell lymphoma.
STATEMENT OF NEED
Mantle cell lymphoma (MCL) is a rare, aggressive B-cell non-Hodgkin lymphoma (NHL) accounting for 5% to 7% of all lymphomas. Its prognosis ranges from indolent disease that does not require treatment for years to very aggressive disease, which is associated with poor survival (Silkenstedt et al, 2021). Typically, MCL is diagnosed at advanced stage and in older patients who cannot tolerate intensive therapy (NCCN, 2022). Although recent advances have slightly increased remission rates, recurrence and relapse remain very common, leading to a median overall survival between 3 and 6 years (LLS, 2021). Though there are several effective options, progress is still needed towards establishing an accepted frontline approach for MCL (Castellino et al, 2022). Treatment selection and management of MCL are complicated by the heterogeneity of prognosis, advanced age and comorbidities of patients, and lack of an established standard approach for treatment, making it vital that clinicians be familiar with the latest research and advances in this area. In this activity chaired by Michael Wang, MD, Professor in the Department of Lymphoma & Myeloma at MD Anderson Cancer Center, expert faculty will discuss prognostic factors informing treatment, the promising results of recent trials in new therapeutic approaches, and the implications of treatment resistance in therapeutic selection for MCL.
Target Audience
Hematology/oncology fellows, attending faculty, and other health care professionals involved in the treatment of patients with mantle cell lymphoma (MCL).
Learning Objectives
1.) Identify clinical and biological prognostic factors that can guide treatment decision making for older adults with MCL
2.) Evaluate emerging data on targeted therapeutic approaches for treatment-naive and relapsed/refractory MCL and their applicability to older adults
3.) Assess mechanisms of resistance to targeted therapies for MCL and their implications for treatment selection
ARTIFICIAL INTELLIGENCE IN HEALTHCARE.pdfAnujkumaranit
Artificial intelligence (AI) refers to the simulation of human intelligence processes by machines, especially computer systems. It encompasses tasks such as learning, reasoning, problem-solving, perception, and language understanding. AI technologies are revolutionizing various fields, from healthcare to finance, by enabling machines to perform tasks that typically require human intelligence.
Pulmonary Thromboembolism - etilogy, types, medical- Surgical and nursing man...VarunMahajani
Disruption of blood supply to lung alveoli due to blockage of one or more pulmonary blood vessels is called as Pulmonary thromboembolism. In this presentation we will discuss its causes, types and its management in depth.
Couples presenting to the infertility clinic- Do they really have infertility...Sujoy Dasgupta
Dr Sujoy Dasgupta presented the study on "Couples presenting to the infertility clinic- Do they really have infertility? – The unexplored stories of non-consummation" in the 13th Congress of the Asia Pacific Initiative on Reproduction (ASPIRE 2024) at Manila on 24 May, 2024.
263778731218 Abortion Clinic /Pills In Harare ,sisternakatoto
263778731218 Abortion Clinic /Pills In Harare ,ABORTION WOMEN’S CLINIC +27730423979 IN women clinic we believe that every woman should be able to make choices in her pregnancy. Our job is to provide compassionate care, safety,affordable and confidential services. That’s why we have won the trust from all generations of women all over the world. we use non surgical method(Abortion pills) to terminate…Dr.LISA +27730423979women Clinic is committed to providing the highest quality of obstetrical and gynecological care to women of all ages. Our dedicated staff aim to treat each patient and her health concerns with compassion and respect.Our dedicated group ABORTION WOMEN’S CLINIC +27730423979 IN women clinic we believe that every woman should be able to make choices in her pregnancy. Our job is to provide compassionate care, safety,affordable and confidential services. That’s why we have won the trust from all generations of women all over the world. we use non surgical method(Abortion pills) to terminate…Dr.LISA +27730423979women Clinic is committed to providing the highest quality of obstetrical and gynecological care to women of all ages. Our dedicated staff aim to treat each patient and her health concerns with compassion and respect.Our dedicated group of receptionists, nurses, and physicians have worked together as a teamof receptionists, nurses, and physicians have worked together as a team wwww.lisywomensclinic.co.za/
Ethanol (CH3CH2OH), or beverage alcohol, is a two-carbon alcohol
that is rapidly distributed in the body and brain. Ethanol alters many
neurochemical systems and has rewarding and addictive properties. It
is the oldest recreational drug and likely contributes to more morbidity,
mortality, and public health costs than all illicit drugs combined. The
5th edition of the Diagnostic and Statistical Manual of Mental Disorders
(DSM-5) integrates alcohol abuse and alcohol dependence into a single
disorder called alcohol use disorder (AUD), with mild, moderate,
and severe subclassifications (American Psychiatric Association, 2013).
In the DSM-5, all types of substance abuse and dependence have been
combined into a single substance use disorder (SUD) on a continuum
from mild to severe. A diagnosis of AUD requires that at least two of
the 11 DSM-5 behaviors be present within a 12-month period (mild
AUD: 2–3 criteria; moderate AUD: 4–5 criteria; severe AUD: 6–11 criteria).
The four main behavioral effects of AUD are impaired control over
drinking, negative social consequences, risky use, and altered physiological
effects (tolerance, withdrawal). This chapter presents an overview
of the prevalence and harmful consequences of AUD in the U.S.,
the systemic nature of the disease, neurocircuitry and stages of AUD,
comorbidities, fetal alcohol spectrum disorders, genetic risk factors, and
pharmacotherapies for AUD.
Title: Sense of Smell
Presenter: Dr. Faiza, Assistant Professor of Physiology
Qualifications:
MBBS (Best Graduate, AIMC Lahore)
FCPS Physiology
ICMT, CHPE, DHPE (STMU)
MPH (GC University, Faisalabad)
MBA (Virtual University of Pakistan)
Learning Objectives:
Describe the primary categories of smells and the concept of odor blindness.
Explain the structure and location of the olfactory membrane and mucosa, including the types and roles of cells involved in olfaction.
Describe the pathway and mechanisms of olfactory signal transmission from the olfactory receptors to the brain.
Illustrate the biochemical cascade triggered by odorant binding to olfactory receptors, including the role of G-proteins and second messengers in generating an action potential.
Identify different types of olfactory disorders such as anosmia, hyposmia, hyperosmia, and dysosmia, including their potential causes.
Key Topics:
Olfactory Genes:
3% of the human genome accounts for olfactory genes.
400 genes for odorant receptors.
Olfactory Membrane:
Located in the superior part of the nasal cavity.
Medially: Folds downward along the superior septum.
Laterally: Folds over the superior turbinate and upper surface of the middle turbinate.
Total surface area: 5-10 square centimeters.
Olfactory Mucosa:
Olfactory Cells: Bipolar nerve cells derived from the CNS (100 million), with 4-25 olfactory cilia per cell.
Sustentacular Cells: Produce mucus and maintain ionic and molecular environment.
Basal Cells: Replace worn-out olfactory cells with an average lifespan of 1-2 months.
Bowman’s Gland: Secretes mucus.
Stimulation of Olfactory Cells:
Odorant dissolves in mucus and attaches to receptors on olfactory cilia.
Involves a cascade effect through G-proteins and second messengers, leading to depolarization and action potential generation in the olfactory nerve.
Quality of a Good Odorant:
Small (3-20 Carbon atoms), volatile, water-soluble, and lipid-soluble.
Facilitated by odorant-binding proteins in mucus.
Membrane Potential and Action Potential:
Resting membrane potential: -55mV.
Action potential frequency in the olfactory nerve increases with odorant strength.
Adaptation Towards the Sense of Smell:
Rapid adaptation within the first second, with further slow adaptation.
Psychological adaptation greater than receptor adaptation, involving feedback inhibition from the central nervous system.
Primary Sensations of Smell:
Camphoraceous, Musky, Floral, Pepperminty, Ethereal, Pungent, Putrid.
Odor Detection Threshold:
Examples: Hydrogen sulfide (0.0005 ppm), Methyl-mercaptan (0.002 ppm).
Some toxic substances are odorless at lethal concentrations.
Characteristics of Smell:
Odor blindness for single substances due to lack of appropriate receptor protein.
Behavioral and emotional influences of smell.
Transmission of Olfactory Signals:
From olfactory cells to glomeruli in the olfactory bulb, involving lateral inhibition.
Primitive, less old, and new olfactory systems with different path